SomnoMed (ASX:SOM) said its revenue for the quarter ended Dec. 31, 2024, grew 20% year-over-year to AU$28.5 million, according to a Friday Australian bourse filing.
Its revenue in the fiscal second quarter reported a jump in all geographies, with North America and Asia-Pacific achieving double-digit increases.
It updated its guidance for the fiscal year ending June 30, now expecting a revenue of about AU$105 million as well as earnings before interest, taxes, depreciation, and amortization of between AU$7 million to AU$9 million.
The firm's shares rose 10% in recent trading on Friday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。